227 related articles for article (PubMed ID: 12072903)
1. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
Schnetzler B; Leger P; Völp A; Dorent R; Pavie A; Gandjbakhch I
Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
[TBL] [Abstract][Full Text] [Related]
2. Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation.
De Santo LS; Della Corte A; Romano G; Amarelli C; Onorati F; Torella M; De Feo M; Marra C; Maiello C; Giannolo B; Casillo R; Ragone E; Grimaldi M; Utili R; Cotrufo M
Transplant Proc; 2004 Apr; 36(3):631-7. PubMed ID: 15110616
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates.
Goland S; Czer LS; Coleman B; De Robertis MA; Mirocha J; Zivari K; Schwarz ER; Kass RM; Trento A
J Heart Lung Transplant; 2008 Oct; 27(10):1115-21. PubMed ID: 18926403
[TBL] [Abstract][Full Text] [Related]
4. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
[TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
6. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
7. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
[TBL] [Abstract][Full Text] [Related]
15. Preoperative single-bolus high-dose antithymocyte globulin as induction therapy in sensitized renal transplant recipients.
Wang D; Wu WZ; Yang SL; Chen JH; Tan JM
Chin Med J (Engl); 2006 Oct; 119(20):1683-8. PubMed ID: 17097014
[TBL] [Abstract][Full Text] [Related]
16. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
Schulz T; Papapostolou G; Schenker P; Kapischke M
Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation.
Mullen JC; Oreopoulos A; Lien DC; Bentley MJ; Modry DL; Stewart K; Winton TL; Jackson K; Doucette K; Preiksaitis J; Halloran PF
J Heart Lung Transplant; 2007 May; 26(5):504-10. PubMed ID: 17449421
[TBL] [Abstract][Full Text] [Related]
18. Influence of induction therapy on rejection and survival in heart transplantation.
Almenar L; García-Palomar C; Martínez-Dolz L; Chamorro C; Moro J; Zorio E; Arnau MA; Rueda J; Osa A; Cardo ML
Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
[TBL] [Abstract][Full Text] [Related]
19. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
